TARS · Tarsus Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio
$75.46
-3.15 (-4.01%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$3.32B
Shares
43.88M
Volume · Oct 1
1.24M
Avg daily vol (3M)
943.54K
Tarsus Pharmaceuticals, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Tarsus Pharmaceuticals, Inc. (TARS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$1.24M
−$15.70M
'21 Q3
21-11-29
▲2858.6%
$10.00M
−$13.60M
'22 Q4
23-03-13
▲363.8%
$2.50M
−$23.42M
'23 Q1
23-05-09
·
$1.87M
−$39.15M
'23 Q3
23-11-09
▲30.8%
$13.08M
−$41.90M
'23 Q4
24-02-27
▲1004.6%
$27.61M
−$35.73M
'24 Q1
24-05-08
·
$40.81M
−$33.29M
'24 Q2
24-08-08
▲2471.8%
$48.12M
−$23.42M
'24 Q3
24-11-13
▲407.9%
$66.41M
−$23.11M
'24 Q4
25-02-25
▲183.7%
$78.33M
−$25.12M
'25 Q1
25-05-01
▲151.5%
$102.66M
−$20.34M
'25 Q2
25-08-06
▲146.7%
$118.70M
−$12.59M
'25 Q3
25-11-04
▲128.4%
$151.67M
−$8.37M
'25 Q4
26-02-23
▲106.9%
$162.05M
−$6.97M
'26 Q1
26-05-06
LATEST
▲69.4%
$173.91M
−$18.55M
'26 Q2
26-08-06
Earnings call
FY26 · Q2
2026-08-06
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2026 Earnings Call Transcript
Confident tone
Alkeas Pharmaceuticals Acquisition / ALK-001
XDEMVI Commercial Performance
Pipeline and Pipeline Prioritization
Revenue
$173.91M
▲ 69.4% YoY Diluted EPS
$-0.43
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Tarsus Pharmaceuticals, Inc. (TARS) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-02
Tarsus Pharmaceuticals, Inc. (TARS) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-26
Tarsus Pharmaceuticals, Inc. (TARS) May 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript
Confident tone
Xdemvy launch momentum and commercial performance
Prescriber depth and ECP adoption
TPO5 Lyme disease prevention program
Revenue
$162.05M
▲ 106.9% YoY Diluted EPS
$-0.16
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-11
Tarsus Pharmaceuticals, Inc. (TARS) March 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-23
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2025 Earnings Call Transcript
Confident tone
Xdenby commercial momentum and peak sales outlook
Payor access and coverage
Seasonality and Q1 dynamics
Revenue
$151.67M*
▲ 128.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2025 Earnings Call Transcript
Confident tone
XdemV/Xtemy commercial launch performance
Direct-to-consumer campaign
Ocular rosacea pipeline
Revenue
$118.70M
▲ 146.7% YoY Diluted EPS
$-0.30
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2025 Earnings Call Transcript
Confident tone
Xdemvy Commercial Launch
Demodex Blepharitis Market Expansion
DTC Campaign Performance
Revenue
$102.66M
▲ 151.5% YoY Diluted EPS
$-0.48
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript
Confident tone
XDEMVY commercial momentum
Pipeline expansion and Ocular Rosacea (TP-04)
Direct-to-consumer campaign
Revenue
$78.33M
▲ 183.7% YoY Diluted EPS
$-0.64
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2024 Earnings Call Transcript
Confident tone
XDEMVY commercial launch and sales growth
Pipeline programs (Ocular Rosacea, TP-04, Lyme)
Direct-to-consumer advertising campaign
Revenue
$66.41M*
▲ 407.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript
Confident tone
Sales force expansion and ECP engagement
XDEMVY launch and sales growth
Evidence generation and clinical data
Revenue
$48.12M
▲ 2471.8% YoY Diluted EPS
$-0.61
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript
Confident tone
XDEMVY launch momentum and sales growth
ECP adoption and prescriber base expansion
Sales force expansion and DTC campaign
Revenue
$40.81M
Diluted EPS
$-0.88
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2024 Earnings Call Transcript
Confident tone
ECP adoption and prescriber base
XDEMVY launch and sales
Sales force and commercial investment expansion
Revenue
$27.61M
▲ 1004.6% YoY Diluted EPS
$-1.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2023 Earnings Call Transcript
Confident tone
Payer coverage and gross-to-net
XDEMVY launch momentum
Demodex blepharitis patient opportunity
Revenue
$13.08M*
▲ 30.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2023 Earnings Call Transcript
Revenue
$1.87M
Diluted EPS
$-1.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2023 Earnings Call
Revenue
$2.50M
▲ 363.8% YoY Diluted EPS
$-0.88
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-13
Tarsus Pharmaceuticals, Inc. (TARS) Q4 2022 Earnings Call
Revenue
$10.00M*
▲ 2858.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-29
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2021 Earnings Call
Revenue
$1.24M
Diluted EPS
$-0.76
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Showing 1–19 of 19 webcasts